



11 September 2020

Sydney, Australia

Corporate Presentation for ShareCafé ‘Hidden Gems’ Webinar

Sydney, 11 September 2020 Nyrada Inc. (ASX:NYR) provides to shareholders and the market generally the corporate presentation for the ShareCafé Small Cap “Hidden Gems” webinar series to be held today, Friday 11 September 2020 from 12:30pm AEST.

Nyrada CEO James Bonnar will provide an overview of the Company’s lead programs and recent progress. The webinar event is free to attend.

To register for the event, please follow the link:

https://us02web.zoom.us/webinar/register/WN_xgg5pzuDQtmC60Y0M6Bs2A.

A replay of the webinar will be made available following the event via the Company’s website at www.nyrada.com.

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological and inflammatory diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited. www.nyrada.com

Authorised by John Moore, Non-Executive Chairman, on behalf of the Board

Investor & Corporate Enquiries:

Prue Kelly
T: 0459 022 445
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com



Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.



Improving Lives, Offering Hope

New Therapies for Cardiovascular & Neurological Diseases

Investor Update

September 2020

Nyrada Programs & Strategy

Drug discoverer
and early stage
developer

Cholesterol lowering drug

Small molecule *PCSK9 inhibitor* to help
people reach their target LDL cholesterol level

Brain injury drug

To help people who sustain a traumatic brain
injury (TBI) or suffer a stroke

Innovative Treatments

Best in Class / First-Line

Clinical Need

Strong Patent Protection

Market Potential


Commercialize Early

Problem – High LDL Cholesterol

High LDL Cholesterol leading cause of cardiovascular disease

Cardiovascular disease responsible for 1 in 4 deaths

62.6 million US adults with elevated LDL-C




Statin Drugs



Low cost



Suboptimal efficacy



27.4 million

US adults with elevated LDL-C are taking a statin

19.4 million

Unable to achieve LDL-C target despite taking statin therapy

Current PCSK9 Inhibitors



Binds to PCSK9 protein

Blocks action of PCSK9
on cholesterol receptor



Effective, combined with statin



Expensive US\$5,800 per year
Inconvenient (2-4 weekly injection)

Statin + current PCSK9 inhibitor = expensive and inconvenient

What is Unique?


Oral PCSK9
treatment

Convenient
for patient

Cost-
effective

Small molecule PCSK9 inhibitor
overcomes longstanding challenge of
oral treatment

Can be combined with statin
to deliver a first ever
single pill PCSK9/statin treatment



Brain Injury Problem


Each year in the US:

- 2.8 million people sustain a traumatic brain injury (TBI)
- 800,000 suffer a stroke


Neurology / physical rehabilitation only existing therapies

- One drug class for stroke (Suitable for less than 15% of patients)
- No treatment exists for TBI


- High mortality
- Severe life-long disability
- High ongoing healthcare cost



Minutes



Hours




Days

Initial injury size

Final injury size

Nyrada Brain Injury Solution

- 📌 Treatment for secondary brain injury following Stroke or TBI
 - Prevent cell death
 - Attenuate damaged brain volume
 - Improve survivability, limit disability, improve quality of life



Program Status & Recent Achievements

Proof-of-concept
established





Lead optimisation well
advanced



First-in-human studies
(Phase I)

- Cholesterol-lowering Drug:
late-2021
- Brain Injury Drug:
mid-2022



-  Nyrada NYX-PCSK9i shows equivalency to Repatha® and Praluent® in human white blood cells
-  Nyrada NYX-1010 showed excellent blood-brain barrier penetration and therapeutic levels in extended dosing study in healthy animal model

Discover More & Follow Us

Nyrada
inc



Neuroprotection Animation



Cholesterol-Lowering Animation

www.nyrada.com



@nyrada_inc



@nyrada_inc



ASX: NYR